Altre lingue Blueprint Medicines Corporation

Azioni

BPMC

US09627Y1091

Mercato chiuso - Nasdaq Altri mercati azionari 22:30:01 03/05/2024			Variaz. 5gg	Var. 1 gen.
107,2 ^USD	+0,18%		+15,26%	+16,21%

02/05	BLUEPRINT MEDICINES CORPORATION : Wedbush ottimista sul caso	ZM
02/05	Le azioni di Blueprint Medicines aumentano dopo che il Q1 ha registrato un utile netto, con un aumento del fatturato	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT/AYVAKYT Full Year Revenue Guidance	03/05
Blueprint Medicines Shares Rise After Q1 Swings to Net Income, Revenue Rises	02/05
Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Posts Q1 Revenue $96.1M, vs. Street Est of $81.4M	02/05
Blueprint Medicines: Q1 Earnings Snapshot	02/05
Blueprint Medicines Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024	02/05
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024	18/04
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics	11/04
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/04
Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing	22/03
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06/03
Blueprint Medicines Insider Sold Shares Worth $500,000, According to a Recent SEC Filing	01/03
Blueprint Medicines Highlights AYVAKIT Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting	26/02
Blueprint Medicines Says Ayvakit Data in Indolent Systemic Mastocytosis Show Long-Term Efficacy, Safety	23/02
Blueprint Medicines Highlights AYVAKIT (Avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting	23/02
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO	22/02
Blueprint Medicines Q4 Loss Narrows, Revenue Rises; Shares Up	15/02
Blueprint Medicines Q4 Loss Narrows, Revenue Rises	15/02
Blueprint Medicines: Q4 Earnings Snapshot	15/02
Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Reports Q4 Revenue $72M, vs. Street Est of $67.1M	15/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Blueprint Medicines Corporation

Azioni

BPMC

US09627Y1091

Altre lingue

Filtri